Genetic Technologies Limited Sponsored ADR Stock

$0.77

0.00%

Nasdaq, Fri, Jun 27 2025

ISIN

US37185R2085

Symbol

GENE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts Strategies

Genetic Technologies Limited Sponsored ADR Stock price

$0.77

-11.69 93.86% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.00 0.00%

ISIN

US37185R2085

Symbol

GENE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$33.8m

Enterprise Value

$33.8m

Net debt

$-90.0k

Cash

$670.0k

Shares outstanding

138.4m

Valuation (TTM | estimate)

P/E

negative | -

P/S

6.75 | -

EV/Sales

6.74 | -

EV/FCF

negative

P/B

88.95

Financial Health

Equity Ratio

29.59%

Return on Equity

-656.53%

ROCE

-540.30%

ROIC

-590.25%

Debt/Equity

0.48

Financials (TTM | estimate)

Revenue

$5.0m | -

EBITDA

$-6.7m | -

EBIT

$-7.0m

Net Income

$-7.9m | -

Free Cash Flow

$-6.3m

Growth (TTM | estimate)

Revenue

-11.64% | -

EBITDA

-9.88% | -

EBIT

-7.81%

Net Income

-2.21% | -

Free Cash Flow

0.31%

Margin (TTM | estimate)

Gross

50.94%

EBITDA

-133.31% | -

EBIT

-140.29%

Net

-156.78% | -

Free Cash Flow

-126.71%

EPS

$-0.06

FCF per Share

$-0.05

Short interest

0.56%

Employees

55.00

Rev per Employee

$90.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Genetic Technologies Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

Financial data from Genetic Technologies Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	5.01 5.01	12% 12% 100%
- Direct Costs	2.46 2.46	13% 13% 49%
Gross Profit	2.55 2.55	10% 10% 51%
- Selling and Administrative Expenses	7.64 7.64	11% 11% 152%
- Research and Development Expense	0.49 0.49	42% 42% 10%
EBITDA	-6.67 -6.67	10% 10% -133%
- Depreciation and Amortization	0.35 0.35	20% 20% 7%
EBIT (Operating Income) EBIT	-7.02 -7.02	8% 8% -140%
Net Profit	-7.85 -7.85	2% 2% -157%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Head office	Australia
CEO	Mr. Morriss
Employees	55
Founded	1987
Website	www.gtglabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now